When the CDC’s newest ADHD numbers landed this week, the question that stuck with me wasn’t about children’s brains. It was: when is the kid’s birthday?
First, the numbers. In 2019, 9.9% of American children aged 5 to 17 had been diagnosed with ADHD at some point in their lives. By 2025 that figure was 13.8%, a relative jump of about 39% in six years, according to a CDC QuickStats report drawn from the National Health Interview Survey. The NCHS data table behind it shows boys going from 13.2% to 17.5%, which means more than one in six school-age boys now carries the label. Girls went from 6.5% to 9.9%. Boys gained more percentage points, but girls rose faster in relative terms, about 52% against roughly 33% for boys.
Here’s why I asked about birthdays. In 2018, a Harvard team led by Timothy Layton and Anupam Jena pulled insurance records on 407,846 children born from 2007 through 2009 and reported in the New England Journal of Medicine that, in states with a September 1 kindergarten cutoff, August-born children were diagnosed with ADHD at 85.1 per 10,000, compared with 63.6 per 10,000 for September-born children. That’s roughly a third more. They were also treated more often, 52.9 versus 40.4 per 10,000. In states with other cutoff dates, the August-September gap shrank to 8.9 per 10,000, and that difference was not statistically significant.
| Group | Value (per 10,000) |
|---|---|
| Born in August | 85.1 |
| Born in September | 63.6 |
So why would the month a child is born change how her attention works? I kept turning that over, and my answer is that it almost certainly doesn’t. What the birth month changes is her seat in the room. In a September-cutoff state, the August kid is the youngest in her class, nearly a year behind the oldest, and a wiggly five-year-old sitting beside a settled six-year-old can look, to a tired adult, like a symptom. That part is my interpretation, since the study can’t say which individual diagnoses were wrong. What it does show is that the school calendar, something that has nothing to do with a child’s nervous system, moves the diagnosis rate.
A shelf, not a slope
Once you know the calendar can push diagnoses around, the shape of the CDC curve starts to look suspicious. The overall figure was 11.6% in 2020, 10.8% in 2021 and 11.5% in 2022, then stepped up to 13.4% in 2023 and stayed there, at 13.6% and 13.8%. Every yearly estimate has a margin of error of roughly a point either way, so I wouldn’t lean too hard on any single year. A sudden step that then holds is still worth chasing. If I had to name the first suspect, it wouldn’t be children’s brains. It would be the referral pipeline: which kids get sent for an evaluation, and what an evaluation now counts as ADHD.
It also helps to know what was actually measured. The survey asks a parent, “Has a doctor or health professional ever told you that [child] had attention-deficit/hyperactivity disorder or ADHD or attention-deficit disorder or ADD?” That is a lifetime label reported at the kitchen table, not a confirmed clinical assessment, and the CDC report doesn’t try to explain why the number moved.
Who’s selling “catch-up”
The mainstream explanation deserves its strongest version. In March, 32 researchers led by Samuele Cortese published a guest editorial, “ADHD (over) diagnosis: fiction, fashion and failure,” in the British Journal of Psychiatry. They argued there is “no good evidence of ADHD being over-diagnosed in the UK” and that the data point to underdiagnosis and unmet need, especially among girls and young adults who used to be missed. Several authors are funded by the UK’s National Institute for Health and Care Research and UK Research and Innovation.
In the US, the clinical trade press met the CDC data with the familiar worry. Contemporary Pediatrics pointed to the 2022 National Survey of Children’s Health, in which 30.1% of children with current ADHD had received no ADHD-specific treatment, behavioral or medical, and concluded that “rising diagnoses do not ensure treatment.” As far as it goes, that’s fair. But the framing takes the label as settled and asks only how to move more labeled kids into care. Whether every one of those labels fits is not the question it asks.
The undertreatment message has a history with money behind it. In 1995, following a PBS investigation, Education Week reported that the leading patient group, CHADD, had taken roughly $818,000 in “educational grants” from Ritalin maker Ciba-Geigy since 1989, and that grants from Ciba-Geigy and other drug companies made up about 20% of its budget. “CHADD is not being bought,” its executive director, Leslie B. Roth, said. That money is thirty years old, and I have no receipt connecting it to anything CHADD says today. It does show how early the industry started paying for the advocacy that was supposed to speak for families.
The catch-up argument also has an arithmetic problem to answer. The BJP authors cite a worldwide figure of about 5% for children and adolescents assessed with structured interviews. The 2022 children’s health survey put current ADHD among American kids aged 3 to 17 at 10.5%, and the new lifetime figure for ages 5 to 17 is 13.8%. These measures cover different ages, definitions and years, so the gap proves nothing by itself. It’s still a gap that “we used to miss people” has to explain.
The net keeps widening
The broadest test of the overdiagnosis question comes from Australia. In 2021, Luise Kazda and colleagues at the University of Sydney screened 12,267 records and included 334 studies, published through August 2020, in a systematic scoping review in JAMA Network Open. Their conclusion was blunt: they found “convincing evidence of ADHD overdiagnosis and overtreatment in children and adolescents.” In 18 of 20 studies that compared diagnostic criteria, broader criteria produced more potential cases. In 8 of 11 studies that tracked impairment as the diagnosed group grew, “impairment levels, adverse outcomes, and benefits of medication substantially decreased.” That’s what you’d expect if the expansion is mostly pulling in milder kids. For those milder cases, the authors wrote, “the harms associated with an ADHD diagnosis may often outweigh the benefits.”
The rise isn’t only happening in the US, either. A Norwegian national registry study published in June, funded by the Norwegian Institute of Public Health, found that new ADHD diagnoses among children and adolescents more than doubled between 2016 and 2024, from 4.4 to 9.0 per 1,000, with the sharpest increase among adolescent girls. That doesn’t prove the two countries share a cause. It does make it harder to blame the whole thing on American telehealth mills or school policy.
An inch for what?
The label matters most for what usually follows it. The American Academy of Pediatrics guideline makes behavioral parent training the first-line approach for preschoolers. For school-age children, it recommends FDA-approved medication along with behavioral and school supports.
So what does years of stimulant use get a child? The best long-run data come from the federally funded Multimodal Treatment Study of ADHD, which randomly assigned 579 elementary-school children to different treatments for 14 months. After that, families made their own choices, which makes the long follow-up observational. The children who stayed on stimulants weren’t chosen at random, and they may have been the most severe cases. With that caveat stated, the adult follow-up led by James Swanson, published in 2017 in the Journal of Child Psychology and Psychiatry, found that participants who took stimulants consistently or on and off ended up 2.55 centimeters shorter as adults than those with negligible use, about an inch. Differences in adult symptom severity between those medication groups were not statistically significant. In the authors’ words, extended use “was associated with suppression of adult height but not with reduction of symptom severity.”
That’s a strange trade when you picture it physically: a drug that a growing body takes through puberty, a measurable shortfall at the end, and no detectable difference in symptoms in adulthood. And it isn’t coming from outsiders looking for a scandal. Swanson has disclosed research, advisory or consulting ties to stimulant makers including Shire, Novartis, Janssen and Lilly.
What I couldn’t find is the evidence that matters most for the children at the new, mild edge of the diagnosis. Across the studies Kazda’s team reviewed, the benefit of medication shrank as the net widened, and a widening net is exactly what the CDC curve looks like. The new federal number doesn’t tell us that American children’s ability to pay attention fell by 39% in six years. It tells us more children are being labeled, the calendar helps decide which ones, and the long-term payoff of the default treatment is still unproven.
If I had a six-year-old and her teacher flagged her tomorrow, I’d check her birthday against the school cutoff first, I’d insist on months of behavioral parent training before any prescription, and I wouldn’t start a stimulant that runs through puberty without a fixed date to stop and reassess.
Sources
- CDC MMWR, QuickStats: Children and adolescents aged 5–17 ever diagnosed with ADHD, by sex and year, 2019–2025 (2026)
- NCHS supplementary data table, National Health Interview Survey 2019–2025
- Layton et al., Attention deficit-hyperactivity disorder and month of school enrollment, New England Journal of Medicine (2018)
- Kazda et al., Overdiagnosis of ADHD in children and adolescents: a systematic scoping review, JAMA Network Open (2021)
- Swanson et al., Young adult outcomes in the follow-up of the MTA: symptom persistence, source discrepancy, and height suppression, Journal of Child Psychology and Psychiatry (2017)
- Incidence of ADHD diagnoses and medication initiation among children and adolescents in Norway, 2016–2024, European Child & Adolescent Psychiatry (2026)
- Cortese et al., ADHD (over) diagnosis: fiction, fashion and failure, British Journal of Psychiatry (2026)
- Danielson et al., ADHD prevalence and treatment among US children, 2022 National Survey of Children’s Health, Journal of Clinical Child & Adolescent Psychology (2024)
- Wolraich et al., AAP clinical practice guideline for ADHD, Pediatrics (2019)
- Contemporary Pediatrics, CDC: ADHD diagnoses in US children rose to 13.8% from 2019 to 2025 (2026)
- Education Week, TV show links ADD support group, drug company (1995)